uniQure Announces Dosing of First Patients in Europe Open-Label Trial of AMT-130katie8288Feb 7, 20220 min read
Skyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's Disease
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
Comments